Warning! GuruFocus detected
3 Severe warning signs
with FYB.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Formycon AG
ISIN : DE000A1EWVY8
Description
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.74 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.17 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.2 | |||||
| Beneish M-Score | -1.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13 | |||||
| 3-Year EPS without NRI Growth Rate | -15.8 | |||||
| 3-Year FCF Growth Rate | -51 | |||||
| 3-Year Book Growth Rate | 71.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.95 | |||||
| 9-Day RSI | 16.63 | |||||
| 14-Day RSI | 18.33 | |||||
| 3-1 Month Momentum % | -4.14 | |||||
| 6-1 Month Momentum % | 2.41 | |||||
| 12-1 Month Momentum % | 5.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | |||||
| Quick Ratio | 2.06 | |||||
| Cash Ratio | 0.89 | |||||
| Days Inventory | 8.13 | |||||
| Days Sales Outstanding | 106.33 | |||||
| Days Payable | 121.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.4 | |||||
| Shareholder Yield % | -18.47 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 12.46 | |||||
| Operating Margin % | -40.64 | |||||
| Net Margin % | 105.09 | |||||
| FCF Margin % | -96.98 | |||||
| ROE % | 12.72 | |||||
| ROA % | 6.97 | |||||
| ROIC % | -2.86 | |||||
| 3-Year ROIIC % | 0.74 | |||||
| ROC (Joel Greenblatt) % | 485.54 | |||||
| ROCE % | 7.36 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 6.41 | |||||
| Forward PE Ratio | 143.1 | |||||
| Shiller PE Ratio | 48.23 | |||||
| Price-to-Owner-Earnings | 6.96 | |||||
| PS Ratio | 7.07 | |||||
| PB Ratio | 0.79 | |||||
| Price-to-Tangible-Book | 64.87 | |||||
| EV-to-EBIT | 7 | |||||
| EV-to-Forward-EBIT | -11.15 | |||||
| EV-to-EBITDA | 6.79 | |||||
| EV-to-Revenue | 7.23 | |||||
| EV-to-Forward-Revenue | 8.69 | |||||
| EV-to-FCF | -7.24 | |||||
| Price-to-GF-Value | 0.36 | |||||
| Price-to-Projected-FCF | 1.46 | |||||
| Price-to-Median-PS-Value | 0.34 | |||||
| Earnings Yield (Greenblatt) % | 14.26 | |||||
| FCF Yield % | -12.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Formycon AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 60.8 | ||
| EPS (TTM) (€) | 4.03 | ||
| Beta | 0.39 | ||
| 3-Year Sharpe Ratio | -0.19 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 59.4 | ||
| 14-Day RSI | 18.33 | ||
| 14-Day ATR (€) | 2.212607 | ||
| 20-Day SMA (€) | 33.815 | ||
| 12-1 Month Momentum % | 5.81 | ||
| 52-Week Range (€) | 24.1 - 64.4 | ||
| Shares Outstanding (Mil) | 17.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Formycon AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Formycon AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Formycon AG Frequently Asked Questions
What is Formycon AG(XTER:FYB)'s stock price today?
The current price of XTER:FYB is €25.30. The 52 week high of XTER:FYB is €64.40 and 52 week low is €24.10.
When is next earnings date of Formycon AG(XTER:FYB)?
The next earnings date of Formycon AG(XTER:FYB) is .
Does Formycon AG(XTER:FYB) pay dividends? If so, how much?
Formycon AG(XTER:FYB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers